NetScientific PLC Portfolio PDS Biotechnology presents at BIO 2016 (3753A)
07 Junho 2016 - 3:01AM
UK Regulatory
TIDMNSCI
RNS Number : 3753A
NetScientific PLC
07 June 2016
NetScientific plc
("NetScientific" or the "Company" or the "Group")
NetScientific Portfolio PDS Biotechnology presents at BIO
2016
NetScientific makes further investment in PDS Biotechnology
London, UK - 7 June 2016 - NetScientific plc (AIM: NSCI), the
transatlantic healthcare technology group, is pleased to note that
its therapeutics portfolio company, PDS Biotechnology, will today
be presenting at BIO 2016 in San Francisco, California. Frank
Bedu-Addo, CEO of PDS Biotechnology, will discuss the recently
announced positive results for the Phase I human clinical trial as
well as PDS's plans for upcoming Phase 2 clinical trials in several
HPV-related cancers, including cervical cancer, head and neck
cancers and intra-epithelial neoplasias as well as prostate,
ovarian, breast and colorectal cancer.
In addition, further to the Company's announcement of 13 April
2016, NetScientific can confirm that it has invested a further
$500,000 in PDS Biotechnology. This investment has been made by way
of a convertible loan, and the funding will be used to assist in
the implementation of its Phase 2 programmes.
Commenting on the news, NetScientific's Chief Executive Officer,
Francois R. Martelet said: "The promising results from PDS's Phase
II results have provided positive validation of the Versamune(R)
T-cell activating platform technology. We now look forward to
continuing our support of this exciting portfolio company as is
looks to further corroborate the potential of PDS0101 in Phase II
development."
The full text of the announcement from PDS Biotechnology can be
found below.
For more information, please contact:
NetScientific Tel: +44 (0)20 3514
François R. Martelet, 1800
M.D., CEO
Mark Nanovich, Interim
CFO
Investec (NOMAD and Tel: +44 (0)20 7597
broker) 4000
Gary Clarence / Daniel
Adams
Consilium Strategic
Communications Tel: +44 (0)20 3709
Mary-Jane Elliott 5700
/ Chris Gardner / netscientific@consilium-comms.com
Jessica Hodgson /
Chris Welsh / Laura
Thornton
About NetScientific
NetScientific is a transatlantic healthcare technology group
with an investment strategy focused on sourcing, funding and
commercialising technologies that significantly improve the health
and well-being of people with chronic diseases. For more
information, please visit the website at www.netscientific.net.
PDS Biotechnology
CEO Frank Bedu-Addo Presenting at BIO 2016
07 June 2016 - PDS Biotechnology, a private clinical stage
immuno-oncology company developing novel immunotherapies, announces
that CEO Frank Bedu-Addo will make a presentation at BIO 2016,
being held at the Moscone Center, 747 Howard Street, San Francisco,
California from June 6-9 2016.
The presentation will be held in Theater 1 on Tuesday, June 7,
commencing at 2:15pm, and provide information on the positive
safety and CD8 + T-cell induction results from the PDS0101 Phase 1
human clinical trial. PDS0101 is the company's lead program based
on its proprietary Versamune(R) T-cell activating platform. Dr.
Bedu-Addo will discuss the unique combination of human safety and
T-cell potency and its impact on enhancing the development of
effective immunotherapies for cancer. The talk will also cover PDS'
plans for upcoming Phase 2 clinical trials in several HPV-related
cancers, as well as other cancers including prostate, ovarian,
breast and colorectal cancers.
The BIO convention brings together over 15,000 biotechnology and
pharma leaders, covering a wide spectrum of life sciences areas
including drug discovery, bio-manufacturing, genomics and more.
About the Versamune(R) T-Cell Activating Platform:
Versamune(R) is a synthetic T-cell activating nanotechnology
that overcomes a key obstacle facing cancer immunotherapy by
facilitating efficient access of cancer protein antigens to
pathways that enable their effective presentation to killer
T-cells. This process trains the body's T-cells to recognize and
efficiently attack the cancer. The ingredient of the Versamune(R)
platform has also been proven to activate critical immunological
signaling pathways that result in the safe production of
immunological proteins known as cytokines and chemokines locally
within the lymph nodes to recruit T-cells, and enhance T-cell
proliferation as well as the killing activity of T-cells.
Activation of these immunological pathways may also be responsible
for the ability of the Versamune(R) -based immunotherapies to
reduce the population of immune suppressive cells and to facilitate
the killing activity of the T-cells specifically within the
tumors.
About PDS Biotechnology:
PDS Biotech is a clinical stage immuno-oncology company
committed to the development of simpler, safer and more effective
immunotherapies. An example of the company's approach is the
Versamune(R) T-cell activating platform, the first immuno-oncology
technology to successfully combine the three critical attributes of
effective immunotherapies in a simple nanoparticle, while also
eliminating the potentially debilitating toxicities of some of the
leading immunotherapy approaches. PDS Biotechnology's oncology
pipeline includes products for prostate, ovarian, breast and
colorectal cancers, in addition to its lead PDS0101 program for
several HPV-related cancers.
Contact Details
PDS Biotechnology Corp.
Frank Bedu-Addo, Ph.D., CEO
Michael King, M.B.A., CFO
Phone: +1-732-640-0145
Email: Execinfo@pdsbiotech.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCLQLLBQQFFBBL
(END) Dow Jones Newswires
June 07, 2016 02:01 ET (06:01 GMT)
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024